What happened Shares of Radius Health (NASDAQ: RDUS), a biopharmaceutical company, are soaring today in response to positive clinical-trial data. Investors excited about elacestrant, an experimental new cancer treatment Radius Health is developing in partnership with the Menarini Group, an Italian company, pushed the stock up 48.8% shortly after the market opened. The stock was still up 34.6% as of 11:25 a.m. EDT on Wednesday. So what Elacestrant is an experimental therapy for breast cancer patients who have tumors that express lots of estrogen receptors but lack receptors for human epidermal growth factor. In the phase 3 Emerald trial with ER+/HER- patients, treatment with elacestrant significantly reduced the risk of death or worsening disease. Image source: Getty Images. Elacestrant is a potential first-in-class selective estrogen receptor degrader (SERD). Luckily, it provided a progression-free survival benefit for the overall population and not just the group of patients with tumors that harbor estrogen receptor 1 mutations. This is a big deal for Radius Health because sales of its lead product, Tymlos, have been somewhat disappointing. The osteoporosis drug reduced patients' long-term risk of vertebral fractures by 87% during trials leading to its approval in 2017. Sales of the daily injection, though, still aren't strong enough to make ends meet. Now what Today's news is a step in the right direction, but Radius Health still hasn't shared the important details. The biotech company will present in-depth results from the Emerald study at the San Antonio Breast Cancer Symposium scheduled for this December. Radius Health finished June with about $100 million in cash after burning through $33 million in the first half of 2021. Unfortunately, the losses will likely continue. Revenue from Tymlos fell to $97 million from $98 million in the first half of 2020. 10 stocks we like better than Radius HealthWhen our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Radius Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source